Avidity Biosciences, Inc. (RNA)
被低估基本面
29
价格
$8.24
市值
$142M
第一部分 · 这家公司值多少
概览
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$36M
最近12个月（截至2026/6/30）
净利润
$-448M
最近12个月（截至2026/6/30）
自由现金流
-
股东权益合计
$1.69B
负债合计
$269M
流动比率
8.73
利息覆盖率
-
债务/EBITDA
-
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$21.12
当前价格
$8.24
安全边际
+61.0%
公允价值区间
$14.39 - $27.84
所用估值方法之间的离散区间，并非经过统计校准的置信区间。
估算方法
估值指标
市盈率（P/E）
-
ROE
-40.5%
市净率（P/B）
0.65
P/FCF
-
毛利率
-
ROIC
-153.3%
盈利能力雷达图
价值创造（经济护城河）
ROIC
-153.3%
WACC
10.9%
ROIC − WACC
-164.2 pp
ROIC 低于资本成本：公司每投入一美元都在毁灭价值。
基本面分析标准
通过（6）
- P/B Ratio 0.65
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 88% Buy
- Earnings Surprise avg 13.1%
未通过（9）
- EPS shows upward trend
- ROIC -153.3%
- Operating Margin -1343.1%
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -40.3%
- Share Dilution 88.9%
- Net Margin Trend -3650.4% vs -2219.9%
- Piotroski F-Score 3/9
不可用（12）
- Historical price data insufficient
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-评分
存在严重财务隐患
盈利质量
低质量：需深入审查会计处理
股权稀释
正在发行新股，稀释所有权
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Ms. Kathleen P. Gallagher | President, CEO & Director | 44 |
| Mr. Brendan Winslow | Chief Financial Officer | 37 |
| Dr. Husam Younis Ph.D., Pharm.D. | Chief Scientific Officer | 51 |
| Ms. Stephanie Kenney | Chief Corporate Affairs Officer | 47 |
| Dr. Steven George Hughes M.B.A., M.D. | Chief Medical Officer | 58 |
| Ms. Rocio Martin Hoyos | Chief Strategy Officer | 42 |
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for RNA, sourced from Markets Gazette.